A little context for the sources
Every source linked in the guide is here. These notes explain what each one adds, without asking you to read every paper.
BPC-157 research
The rat stomach-ulcer study compared muscle and stomach delivery. It found better ulcer healing, with the muscle route doing better. It didn't test human sublingual use.
The two-adult intravenous safety report reported no adverse events in two people who had received BPC-157 this way before. There was no comparison group. It can't settle long-term safety or treatment benefit.
The review of BPC-157 research describes broad animal research beside very limited human evidence. A review brings existing work together; it isn't another trial.
The blood tests in that pilot were safety markers. They weren't measurements of how much drug crossed a surface under the tongue. Finding no change in a few tests also doesn't rule out effects the report wasn't set up to find.
CJC-1295 research
The early human study measured growth hormone and a related growth signal after injections under the skin in healthy adults. These weren't measurements of better sleep or recovery.
The FDA review of CJC-1295 explains the difference between forms with and without DAC. It also discusses side effects and gaps in the human research. The studied material appears to have been the DAC form, with its exact salt unspecified.
Hormone measurements can show a biological response without showing that someone slept better or recovered from an injury. The result and the claimed benefit still have to match.
Semaglutide products and outcomes
The swallowed-tablet prescribing information is for specific approved semaglutide products. It isn't evidence for sublingual versions of other peptides.
The weight-management trial studied injections in adults without diabetes who had obesity, or overweight plus a weight-related health condition. Both groups had lifestyle support. Average weight loss was greater with semaglutide than placebo.
The semaglutide product label gives warnings and side effects. Those cautions belong beside the findings about benefit.
The tablet information and the injection trial answer different questions about different products. Reading them together doesn't turn them into a study of a sublingual preparation. The route remains part of the finding.
FDA explanations
The FDA compounding Q&A distinguishes compounded medicines from approved products. The compounded-drug risks page explains what FDA doesn't check before they're marketed.
On the safety-risk page current as of April 22, 2026, BPC-157 and CJC-1295 are listed as nominated but withdrawn. FDA still prints safety concerns beside them. It gives no withdrawal dates, and withdrawal isn't clearance or permission to compound.